Developing a new method for quickly detecting filoviruses like Ebola and Marburg.
Official title: PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response.
Funded at Aldatu Biosciences, INC. · NIH-10899546 · Data updated 2026-11-12
This study is working on a new way to quickly and accurately detect Ebola and Marburg viruses, which cause serious illnesses, so that we can better manage outbreaks and keep people safe.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aldatu Biosciences, INC. NIH-funded |
| Lab location | 1 site (Watertown, UNITED STATES) |
| Project start | August 1, 2022 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $943,229 |
| NIH project number | 5R44AI172551-03 |
| Project ID | NIH-10899546 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals in regions where filovirus outbreaks occur, particularly those showing symptoms consistent with hemorrhagic fevers.
✕Less likely to help
Patients who are not in outbreak areas or do not exhibit symptoms related to filovirus infections may not benefit from this research.
What this research studies
This research focuses on improving the detection of filoviruses, specifically Ebolavirus and Marburgvirus, which cause severe hemorrhagic fevers. The current diagnostic methods struggle due to the genetic variability of these viruses, making early detection challenging. The study utilizes a novel technology called PANDAA, which enhances the accuracy of qPCR tests by adapting to diverse viral genetic sequences. This approach aims to provide rapid and reliable diagnostics to help control outbreaks effectively.
Why it matters
Potential benefit: If successful, this research could lead to faster and more accurate detection of filoviruses, improving outbreak response and patient outcomes.
How similar studies have gone: Previous research has shown promise in developing rapid diagnostic methods for other infectious diseases, suggesting potential success for this novel approach.
Where this research is happening
-
Aldatu Biosciences, INC.
Watertown, United States Active
Researchers
- Principal investigator: Macleod, Iain James — Aldatu Biosciences, INC.
- Study coordinator: Macleod, Iain James
Related research
Other NIH-funded projects on the same topics.
-
PANDAA universal test for Crimean-Congo hemorrhagic fever (CCHFV)
A new rapid diagnostic test aims to detect all lineages of Crimean-Congo hemorrhagic fever virus to help people with fever symptoms get timely answers and care.
-
PANDAA: a universal test to quickly identify filoviruses during outbreaks
A new broad-range diagnostic test aims to rapidly detect and tell apart Ebola and Marburg viruses in people during outbreaks.
-
Universal molecular test for Crimean‑Congo hemorrhagic fever
A rapid molecular test that can detect all genetic variants of the virus that causes Crimean‑Congo hemorrhagic fever in people with suspected infection.
-
Developing a universal test for Crimean-Congo Hemorrhagic Fever virus.
This study is working on a new test called PANDAA that helps quickly and accurately find the Crimean-Congo hemorrhagic fever virus, even in its early stages, making it easier for doctors to diagnose patients in areas where this illness is common.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.